344 related articles for article (PubMed ID: 34436747)
1. Unravelling the potential neuroprotective facets of erythropoietin for the treatment of Alzheimer's disease.
Kaur D; Behl T; Sehgal A; Singh S; Sharma N; Badavath VN; Ul Hassan SS; Hasan MM; Bhatia S; Al-Harassi A; Khan H; Bungau S
Metab Brain Dis; 2022 Jan; 37(1):1-16. PubMed ID: 34436747
[TBL] [Abstract][Full Text] [Related]
2. The Promises and Challenges of Erythropoietin for Treatment of Alzheimer's Disease.
Sun J; Martin JM; Vanderpoel V; Sumbria RK
Neuromolecular Med; 2019 Mar; 21(1):12-24. PubMed ID: 30656553
[TBL] [Abstract][Full Text] [Related]
3. Improvement of memory deficits in the rat model of Alzheimer's disease by erythropoietin-loaded solid lipid nanoparticles.
Dara T; Vatanara A; Sharifzadeh M; Khani S; Vakilinezhad MA; Vakhshiteh F; Nabi Meybodi M; Sadegh Malvajerd S; Hassani S; Mosaddegh MH
Neurobiol Learn Mem; 2019 Dec; 166():107082. PubMed ID: 31493483
[TBL] [Abstract][Full Text] [Related]
4. Multifaceted Alzheimer's Disease: Building a Roadmap for Advancement of Novel Therapies.
Kaur D; Behl T; Sehgal A; Singh S; Sharma N; Bungau S
Neurochem Res; 2021 Nov; 46(11):2832-2851. PubMed ID: 34357520
[TBL] [Abstract][Full Text] [Related]
5. Intranasal formulation of erythropoietin (EPO) showed potent protective activity against amyloid toxicity in the Aβ₂₅₋₃₅ non-transgenic mouse model of Alzheimer's disease.
Maurice T; Mustafa MH; Desrumaux C; Keller E; Naert G; de la C García-Barceló M; Rodríguez Cruz Y; Garcia Rodríguez JC
J Psychopharmacol; 2013 Nov; 27(11):1044-57. PubMed ID: 23813967
[TBL] [Abstract][Full Text] [Related]
6. Molecular Insight into the Therapeutic Promise of Flavonoids against Alzheimer's Disease.
Uddin MS; Kabir MT; Niaz K; Jeandet P; Clément C; Mathew B; Rauf A; Rengasamy KRR; Sobarzo-Sánchez E; Ashraf GM; Aleya L
Molecules; 2020 Mar; 25(6):. PubMed ID: 32168835
[TBL] [Abstract][Full Text] [Related]
7. Activation of migration of endogenous stem cells by erythropoietin as potential rescue for neurodegenerative diseases.
Khairallah MI; Kassem LA; Yassin NA; Gamal el Din MA; Zekri M; Attia M
Brain Res Bull; 2016 Mar; 121():148-57. PubMed ID: 26802509
[TBL] [Abstract][Full Text] [Related]
8. An Intranasal Formulation of Erythropoietin (Neuro-EPO) Prevents Memory Deficits and Amyloid Toxicity in the APPSwe Transgenic Mouse Model of Alzheimer's Disease.
Rodríguez Cruz Y; Strehaiano M; Rodríguez Obaya T; García Rodríguez JC; Maurice T
J Alzheimers Dis; 2017; 55(1):231-248. PubMed ID: 27662300
[TBL] [Abstract][Full Text] [Related]
9. Towards development of drugs targeting both amyloid and tau pathologies of Alzheimer's disease.
Shin J
Int J Geriatr Psychiatry; 2011 May; 26(5):546-8. PubMed ID: 21446001
[No Abstract] [Full Text] [Related]
10. Neuroprotective effects of multifaceted hybrid agents targeting MAO, cholinesterase, iron and β-amyloid in ageing and Alzheimer's disease.
Weinreb O; Amit T; Bar-Am O; Youdim MB
Br J Pharmacol; 2016 Jul; 173(13):2080-94. PubMed ID: 26332830
[TBL] [Abstract][Full Text] [Related]
11. Liraglutide and a lipidized analog of prolactin-releasing peptide show neuroprotective effects in a mouse model of β-amyloid pathology.
Holubová M; Hrubá L; Popelová A; Bencze M; Pražienková V; Gengler S; Kratochvílová H; Haluzík M; Železná B; Kuneš J; Hölscher C; Maletínská L
Neuropharmacology; 2019 Jan; 144():377-387. PubMed ID: 30428311
[TBL] [Abstract][Full Text] [Related]
12. Berberine: A Plant-derived Alkaloid with Therapeutic Potential to Combat Alzheimer's disease.
Singh AK; Singh SK; Nandi MK; Mishra G; Maurya A; Rai A; Rai GK; Awasthi R; Sharma B; Kulkarni GT
Cent Nerv Syst Agents Med Chem; 2019; 19(3):154-170. PubMed ID: 31429696
[TBL] [Abstract][Full Text] [Related]
13. Why Is Research on Amyloid-β Failing to Give New Drugs for Alzheimer's Disease?
Doig AJ; Del Castillo-Frias MP; Berthoumieu O; Tarus B; Nasica-Labouze J; Sterpone F; Nguyen PH; Hooper NM; Faller P; Derreumaux P
ACS Chem Neurosci; 2017 Jul; 8(7):1435-1437. PubMed ID: 28586203
[TBL] [Abstract][Full Text] [Related]
14. Neuropep-1 ameliorates learning and memory deficits in an Alzheimer's disease mouse model, increases brain-derived neurotrophic factor expression in the brain, and causes reduction of amyloid beta plaques.
Shin MK; Kim HG; Baek SH; Jung WR; Park DI; Park JS; Jo DG; Kim KL
Neurobiol Aging; 2014 May; 35(5):990-1001. PubMed ID: 24268884
[TBL] [Abstract][Full Text] [Related]
15. Phenylpropanoids and Alzheimer's disease: A potential therapeutic platform.
Kolaj I; Imindu Liyanage S; Weaver DF
Neurochem Int; 2018 Nov; 120():99-111. PubMed ID: 30098379
[TBL] [Abstract][Full Text] [Related]
16. Radiation Therapy in Alzheimer's Disease: A Systematic Review.
Kaul D; Ehret F; Roohani S; Jendrach M; Buthut M; Acker G; Anwar M; Zips D; Heppner F; Prüss H
Int J Radiat Oncol Biol Phys; 2024 May; 119(1):23-41. PubMed ID: 38042449
[TBL] [Abstract][Full Text] [Related]
17. Erythropoietin improves synaptic plasticity and memory deficits by decrease of the neurotransmitter release probability in the rat model of Alzheimer's disease.
Esmaeili Tazangi P; Moosavi SM; Shabani M; Haghani M
Pharmacol Biochem Behav; 2015 Mar; 130():15-21. PubMed ID: 25553822
[TBL] [Abstract][Full Text] [Related]
18. Short erythropoietin-derived peptide enhances memory, improves long-term potentiation, and counteracts amyloid beta-induced pathology.
Dmytriyeva O; Belmeguenai A; Bezin L; Soud K; Drucker Woldbye DP; Gøtzsche CR; Pankratova S
Neurobiol Aging; 2019 Sep; 81():88-101. PubMed ID: 31255922
[TBL] [Abstract][Full Text] [Related]
19. Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease.
McClean PL; Hölscher C
Neuropharmacology; 2014 Jan; 76 Pt A():57-67. PubMed ID: 23973293
[TBL] [Abstract][Full Text] [Related]
20. Peptide Derivatives of Erythropoietin in the Treatment of Neuroinflammation and Neurodegeneration.
Ercan I; Tufekci KU; Karaca E; Genc S; Genc K
Adv Protein Chem Struct Biol; 2018; 112():309-357. PubMed ID: 29680240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
